Carol Burt
Known title: DirectorCIK: 0001493926
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
ResMed Q4 2026 Earnings Call Transcript Released. ResMed has released the transcript for its Q4 2026 earnings call, providing investors with detailed insights into the company's recent performance. This follows a quarterly earnings preview and places the stock within a broader market forecast for the mHealth sector. The release offers a factual record of management's comments on financial results and strategic direction.
Transaction History
| IQV | ▲ Buy | Grant | 1,571 | $0 | 4/23/2026 | View on chart |
| RMD | ▲ Buy | Grant | 1,073 | $0 | 11/20/2025 | View on chart |
| RMD | ▲ Buy | Grant | 1,083 | $0 | 11/20/2024 | View on chart |
| RMD | ▼ Sell | Gift | 47 | $0 | 5/24/2024 | View on chart |
| RMD | ▼ Sell | Gift | 234 | $0 | 4/29/2024 | View on chart |
| RMD | ▲ Buy | Grant | 1,768 | $0 | 11/16/2023 | View on chart |
| IQV | ▲ Buy | Grant | 1,063 | $0 | 5/10/2023 | View on chart |
| RMD | ▲ Buy | Grant | 1,122 | $0 | 11/16/2022 | View on chart |
| IQV | ▲ Buy | Grant | 995 | $0 | 5/11/2022 | View on chart |
| RMD | ▼ Sell | Open Market | 1,500 | $390K | 11/22/2021 | View on chart |
| RMD | ▲ Buy | Grant | 956 | $0 | 11/18/2021 | View on chart |
| RMD | ▼ Sell | Open Market | 1,187 | $321K | 11/15/2021 | View on chart |
| RMD | ▼ Sell | Gift | 347 | $0 | 8/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
IQVIA Expands Veeva Partnership and Raises Price Targets
IQVIA announced an expanded partnership with Veeva Systems to use clinical operations software across its development studies. This move coincides with reports of an improving demand environment and high win rates. Stifel recently raised its price target for the stock to $303, reflecting confidence in the company's backlog and operational updates.
IQVIA Expands Veeva Partnership and Raises Price Targets. IQVIA announced an expanded partnership with Veeva Systems to use clinical operations software across its development studies. This move coincides with reports of an improving demand environment and high win rates. Stifel recently raised its price target for the stock to $303, reflecting confidence in the company's backlog and operational updates.